{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Figure 1:', 'TCGA Immune Signatures Using CDSA/PD-1/PD-L1 Expression', 'LGG', 'Brain lower grade glioma (n=534)', 'GBM', 'Glioblastoma multiforme (n=169)', 'PCPG', 'Pheochromocytoma and Paraganglioma (n=184)', 'UCS', 'Uterine carcinosarcoma (n=57)', 'ACC', 'Adrenocortical carcinoma (n=79)', 'PRAD', 'Prostate adenocarcinoma (n=502)', 'READ', 'Rectum adenocarcinoma (n=167)', 'UVM', 'Uveal melanoma (n=80)', 'OV', 'Ovarian serous cystadenocarcinoma (n=430)', 'COAD', 'Colon adenocarcinoma (n=473)', 'BRCA', 'Breast invasive carcinoma (n=1114)', 'PAAD', 'Pancreatic adenocarcinoma (n=179)', 'ESCA', 'Esophageal carcinoma (n=185)', 'KIRP', 'Kidney renal papillary cell carcinoma (n=291)', 'THCA', 'Thyroid carcinoma (n=513)', 'BLCA', 'Bladder urothelial carcinoma (n=411)', 'LIHC', 'Liver hepatocellular carcinoma (n=374)', 'UCEC', 'Uterine corpus endometrial carcinoma (n=551)', 'CHOL', 'Cholangiocarcinoma (n=36)', 'SARC', 'Sarcoma (n=263)', 'STAD', 'Stomach adenocarcinoma (n=420)', 'MESO', 'Mesothelioma (n=87)', 'TGCT', 'Testicular germ cell tumors (n=156)', 'KICH', 'Kidney Chromophobe (n=66)', 'HNSC', 'Head and Neck squamous cell carcinoma (n=522)', 'LUSC', 'Lung squamous cell carcinoma (n=501)', 'LUAD', 'Lung adenocarcinoma (n=530)', 'CESC', 'Cervical SCC and endocervix adenoca. (n=306)', 'KIRC', 'Kidney renal clear cell carcinoma (n=538)', 'SKCM', 'Skin Cutaneous Melanoma (n=472)', 'CD8A PD-1 PD-L1', 'Positive PD1 blockade phase 3 data', '-3.11 0.00 3.11', 'Source: Regeneron Molecular Profiling analysis of TCGA RNA-Seq data.', 'Color key of Z value is shown.', 'Additional background information on the study drug and development program can be found in', \"the Investigator's Brochure.\", '2.', 'STUDY OBJECTIVES', '2.1.', 'Primary Objective', 'To compare os for patients with recurrent or metastatic cervical cancer who have histology of', 'squamous cell carcinoma (SCC) and who have any eligible histology, treated with either', \"cemiplimab or investigator's choice (IC) chemotherapy.\", '2.2.', 'Secondary Objectives', 'The secondary objectives of the study performed among SCC patients and among all eligible', 'histologies (SCC and adenocarcinoma/adenosquamous carcinoma [AC]) are:', 'To compare progression-free survival (PFS) of cemiplimab versus IC chemotherapy', 'To compare objective response rate (ORR) (partial response [PR] + CR) of', 'cemiplimab versus IC chemotherapy per Response Evaluation Criteria in Solid', 'Tumors (RECIST) 1.1 (Appendix 1)', 'To compare the duration of response (DOR) of cemiplimab versus IC chemotherapy', 'Regeneron Pharmaceuticals, Inc.', 'Page 37 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'To compare the safety profiles of cemiplimab versus IC chemotherapy by describing', 'adverse events (AE)', 'To compare quality of life (QOL) for patients treated with cemiplimab versus IC', 'chemotherapy using European Organization for Research and Treatment of Cancer', 'Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)', '2.3.', 'Exploratory Objectives', 'To measure concentrations of cemiplimab in serum and characterize the', 'pharmacokinetics (PK) of cemiplimab', 'To assess the immunogenicity of cemiplimab', 'To explore associations between the clinical efficacy of cemiplimab and molecular', 'features in pretreatment tumor samples', 'To explore the pharmacodynamic activity of cemiplimab on the immune system in', 'peripheral blood samples', '3.', 'HYPOTHESIS AND RATIONALE', '3.1.', 'Hypothesis', 'Human papillomavirus viral proteins are recognized as foreign antigens by effector T cells in', 'cervical cancer, and an anti-tumor immune response can be unleashed by blockade of the PD-1', 'immune checkpoint. Cemiplimab will improve os compared to IC chemotherapy for cervical', 'cancer patients who experienced progression of disease after treatment with platinum', 'chemotherapy that was administered in the recurrent or metastatic disease setting, in SCC and in', 'the overall population.', '3.2.', 'Rationale', '3.2.1.', 'Rationale for Patient Population and Study Design', 'This is an open-label, randomized, phase 3 trial of cemiplimab versus IC chemotherapy in patients', 'with recurrent or metastatic cervical cancer that has progressed after platinum-containing', 'chemotherapy. The GOG240 study established the efficacy of first line-therapy for recurrent or', 'metastatic cervical cancer with the regimen of platinum + paclitaxel + bevacizumab (Tewari 2014).', 'There is no standard-of-care regimen in the second line setting. Agents that may be considered in', 'this setting are the IC options in this study: pemetrexed, topotecan, irinotecan, gemcitabine, and', 'vinorelbine. Despite the availability of various chemotherapy options, patients treated with these', 'agents for cervical cancer have a median survival time of approximately 7 months (Section 3.2.3).', 'A concept of \"platinum-refractory\" disease has been described in the cervical cancer literature,', 'and is related to time since prior platinum therapy (Nishino 2016) (McLachlan 2016)', '(Tanioka 2011). However, it is not typical clinical practice to re-treat cervical cancer patients with', 'platinum-based chemotherapy if they have already received it in the setting of recurrent or', 'metastatic disease. The chemotherapy regimens in the control arm of this study represent the', 'current treatment options for cervical cancer patients who have received prior platinum in the', 'Regeneron Pharmaceuticals, Inc.', 'Page 38 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}